No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LRMR240621C15000
- 0.18
- 0.000.00%
15min DelayTrading Jun 3 09:30 ET
0.18High0.18Low
0.18Open0.18Pre Close2 Volume0 Open Interest15.00Strike Price36.00Turnover175.72%IV72.70%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.18Extrinsic Value100Contract SizeAmericanOptions Type0.1233Delta0.0589Gamma48.83Leverage Ratio-0.0189Theta0.0005Rho6.02Eff Leverage0.0040Vega
Intraday
- 5D
- 1D
News
Larimar Therapeutics Insiders Placed Bullish Bets Worth US$540.7k
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in Larimar Therapeutics, Inc.'s (NASDAQ:LRMR) instance, it's good news for
Health Care Stocks Climb On Drug News -- Health Care Roundup
Health-care company shares climbed amid positive news for drug makers. The Food and Drug Administration approved Moderna's vaccine to protect against respiratory syncytial virus, a common virus that
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results.SentinelOne reported quarterly losses of 23 cents per share, which
Larimar Therapeutics Shares Rise 15% Nomlabofusp Selected for FDA Program
By Chris Wack Larimar Therapeutics shares were up 15% at $8.17 after the company said the Food and Drug Administration has selected nomlabofusp to participate in the Support for Clinical Trials Advan
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Nasdaq Composite falling around 1% on Friday.Shares of Ambarella, Inc. (NASDAQ:AMBA) rose sharply during Friday's session following strong first-quarter earnings and u
Buy Rating Affirmed for Larimar Therapeutics as FDA Accelerates Nomlabofusp's Path in START Pilot Program
Comments
$Larimar Therapeutics(LRMR.US$ Reuters· 2 mins ago
Larimar Therapeutics Inc: Selected by FDA to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia
Larimar Therapeutics Inc: Selected by FDA to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia
$Larimar Therapeutics(LRMR.US$
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
Larimar Therapeutics announced that the FDA has selected its therapy, nomlabofusp, for the START pilot program. This program aims to accelerate the development of treatments for rare diseases. Nomlabofusp is a novel protein replacement therapy targeting the root cause of Friedreich’s ataxia (FA) by delivering frataxin to mitochondria.
The selection...
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
Larimar Therapeutics announced that the FDA has selected its therapy, nomlabofusp, for the START pilot program. This program aims to accelerate the development of treatments for rare diseases. Nomlabofusp is a novel protein replacement therapy targeting the root cause of Friedreich’s ataxia (FA) by delivering frataxin to mitochondria.
The selection...
1
Clinical Updates💉
⇒ $Larimar Therapeutics(LRMR.US$ 🟢
‣ FDA removes partial clinical hold
‣ Nomlabofusp (CTI-1601) #FA
‣ Protein replacement therapy
‣ Interim data from OLE in Q4 '24 🔔
Clinical readouts 📢
⇒ $Citius Pharmaceuticals(CTXR.US$ 🟢
‣ Positive Ph3 topline results
‣ Mino-Lok® #CLABSI #CRBSI
‣ Antibiotic lock solution
‣ Overall treatment success in 57.1% patients
Regulatory Update🎯
⇒ $Halozyme Therapeutics(HALO.US$ $Bristol-Myers Squibb(BMY.US$
‣ FDA Reassigned PDUFA data to 12/29/24
‣ Subcutane...
⇒ $Larimar Therapeutics(LRMR.US$ 🟢
‣ FDA removes partial clinical hold
‣ Nomlabofusp (CTI-1601) #FA
‣ Protein replacement therapy
‣ Interim data from OLE in Q4 '24 🔔
Clinical readouts 📢
⇒ $Citius Pharmaceuticals(CTXR.US$ 🟢
‣ Positive Ph3 topline results
‣ Mino-Lok® #CLABSI #CRBSI
‣ Antibiotic lock solution
‣ Overall treatment success in 57.1% patients
Regulatory Update🎯
⇒ $Halozyme Therapeutics(HALO.US$ $Bristol-Myers Squibb(BMY.US$
‣ FDA Reassigned PDUFA data to 12/29/24
‣ Subcutane...
4
$Larimar Therapeutics(LRMR.US$
NEWS
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
Larimar Therapeutics (Nasdaq: LRMR) announced that the FDA has removed the partial clinical hold on their nomlabofusp (CTI-1601) program, aimed at treating Friedreich’s Ataxia (FA). This decision followed the review of data from a recently completed Phase 2 dose exploration study, which included 25 mg and 50 mg cohorts. The study showed that nom...
NEWS
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
Larimar Therapeutics (Nasdaq: LRMR) announced that the FDA has removed the partial clinical hold on their nomlabofusp (CTI-1601) program, aimed at treating Friedreich’s Ataxia (FA). This decision followed the review of data from a recently completed Phase 2 dose exploration study, which included 25 mg and 50 mg cohorts. The study showed that nom...
1
2
Read more